Boston Scientific’s full acquisition of Farapulse affirms its confidence that pulsed field ablation (PFA) technology can accelerate the growth of its electrophysiology business.
Boston Scientific first invested in Farapulse in 2014 and currently owns 27% of the Menlo Park, CA-based company
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?